Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …

We describe a patient with seropositive rheumatoid arthritis who developed pachymeningitis
resulting in optic atrophy. Clinical, histopathologic, and radiologic findings in 18 additional …

… Bathon has received consulting fees, speaking fees, and/or honoraria from Gilead … Schoe
A, van der Laan- Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis …

Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Objective. To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab
(anti–tumor necrosis factor [anti-TNF] monoclonal antibody) with those of MTX treatment …

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

Background: Disease-modifying antirheumatic drugs may confer greater benefits when
combined with the antimetabolite methotrexate. Objective: To evaluate the efficacy and safety of …

… Bathon has received consulting fees or honoraria (less than $10,000 per year) from Centocor
and Synta Pharma and has grant support or contracts from Amgen, Bristol-Myers Squibb, …

Objective To assess whether it is better to intensively treat all patients with early rheumatoid
arthritis (RA) using combinations of drugs or to reserve this approach for patients who do not …

The ability to target and neutralize macrophage-derived inflammatory cytokines, particularly
tumor necrosis factor–α (TNF-α), has emerged in recent years as one of the most important …